In a nutshell This study examined if brachytherapy, a type of radiotherapy, is more effective with or without hormonal therapy for patients with localized prostate cancer. The authors found that patients survived longer without cancer worsening after treatment with brachytherapy and hormonal therapy. Some background Brachytherapy (BT) is a type...
Read More
In a nutshell The study investigated the use of relugolix (Relumina), a hormonal therapy drug, in addition to radiotherapy (RT), in managing prostate cancer. The study found that relugolix was effective in reducing androgen (male sex hormones such as testosterone) levels and well tolerated in these patients. Some background Prostate...
Read More
In a nutshell The study looked at the effects of long term androgen deprivation therapy (LT-ADT), pelvic lymph node radiotherapy (PLNRT) and prostate bed radiotherapy (PBRT) in patients with prostate cancer and high risk of recurrence after prostate surgery. They found an increase in survival without cancer worsening in these patients. Some...
Read More
In a nutshell This study compared 6-month and 18-month courses of hormonal anti-androgen treatment and radiotherapy (RT) in patients with locally advanced prostate cancer (LAPC). The results showed that 18-month treatment was most effective, especially when used with high dose brachytherapy RT. Some background Androgens (such as testosterone) are...
Read More
In a nutshell This study examined if the frequency of the same dose of radiotherapy (RT) changed the effectiveness and safety of patients with localized prostate cancer (PC). The results showed that RT that was given weekly was as effective and safe as RT given every other day. Some background Radiotherapy (RT) is an effective treatment for...
Read More
In a nutshell The study compared the long-term outcomes of prostate surgery (radical prostatectomy; RP) and observation (watchful waiting; WW) in patients with early prostate cancer. The study showed that surgery reduced mortality in these patients. Some background Prostate cancer is one of the most common cancers in American men....
Read More
In a nutshell This article reviewed treatment options for patients with high-risk prostate cancer. Some background Prostate cancer is a cancer that starts in the prostate gland. There are different types of treatment for patients with prostate cancer. Treatment choice depends on disease stage or whether the cancer has spread to other parts of the...
Read More
In a nutshell This study aimed to investigate results reported by patients with prostate cancer following moderately hypofractionated (H-RT) or conventionally fractionated radiation therapy (C-RT). The main outcome was that men who had undergone H-RT showed greater improvements in sexual and hormonal activity than those who had undergone C-RT. Some...
Read More
In a nutshell This study analyzed the health-related quality of life (HRQOL) in patients with metastatic castration-sensitive prostate cancer (MCSPC) after treatment with apalutamide (Erleada) and androgen deprivation therapy (ADT). The study found that apalutamide plus ADT was well tolerated and improved survival compared to ADT alone in these...
Read More
In a nutshell This study compared the safety and effectiveness of short-term androgen deprivation therapy (ADT) combined with radiotherapy (RT) in patients who underwent radical prostatectomy (RP). The main finding was that the combination of ADT and RT reduced the risk of recurrence and disease progression in these patients. Some background RP is...
Read More
In a nutshell This study evaluated the order of treatment with two different hormone therapy drugs in patients with castration-resistant prostate cancer that has spread. This study found that treatment with abiraterone acetate (Yonsa) then enzalutamide (Xtandi) delayed cancer growth or spread longer than the same drugs in the opposite...
Read More
In a nutshell This study evaluated if the benefit of adding abiraterone acetate (Zytiga) + prednisone (Deltasone) to androgen-deprivation therapy (ADT) in treating metastatic, castration-sensitive prostate cancer (mCSPC) would be maintained in patients treated with ADT alone. This study concluded that this treatment...
Read More
